Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Sensipar / Mimpara (cinacalcet by Year
Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — U.S. product sales ($M) ($M)
Amgen Sensipar / Mimpara (cinacalcet: $10M in FY2022, up 66.7% from a year earlier. No newer figure appears in the documents we track.
Where the FY2022 figure comes from
“|| Sensipar — U.S. | 10 | 67 | % | 6 | (93) | % | 92”
Source: Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Sensipar / Mimpara (cinacalcet — Secondary Hyperparathyroidism, legacy standalone disclosure) — U.S. product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 10 | +66.7% | Form 10-K (amgn-20221231.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 6 | -93.5% | Form 10-K (amgn-20211231.htm, filed 2022-02-16) ↗ |
| FY2020 | Dec 31, 2020 | 92 | -63.5% | Form 10-K (amgn-20201231.htm, filed 2021-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 252 | -82.5% | Form 10-K (filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 1,436 | +4.5% | Form 10-K (filed 2019-02-13) ↗ |
| FY2017 | Dec 31, 2017 | 1,374 | +10.8% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 1,240 | – | Form 10-K (filed 2019-02-13) ↗ |
Cite this data
StockData. (2026). Amgen Sensipar / Mimpara (cinacalcet ($M), annual FY2016–FY2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-sensipar-us
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.